IBD Forum 2020 - Newport Beach, CA

Event Information

Share this event

Date and Time



Newport Beach Marriott Hotel and Spa

900 Newport Center Drive

Salon E&F, Lobby Level

Newport Beach, California 92660

View Map

Event description


Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, affects an estimated 3 million adults in the United States and is increasing in incidence and prevalence. In the quest to optimize outcomes, clinicians providing care to patients with IBD face numerous challenges, including the determination of disease severity, treating the newly diagnosed patient, understanding and incorporating the use of available biologic agents and newer treatments with novel mechanisms of action, and applying strategies for therapeutic drug monitoring. Therefore, education is vital to help clinicians stay abreast of the latest evidence-based management approaches. The faculty of IBD Forum 2020 will review the current IBD guidelines, biologic agents, combination therapies, measures that will improve clinician–patient communication, and other identified educational gaps.

Course Chair

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA


Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL

Peter D.R. Higgins, MD, PhD, MSc
Professor of Internal Medicine
University of Michigan
Ann Arbor, MI

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC


7:30 AM
Registration and Breakfast

8:00 AM
Introduction and Pretest

8:15 AM
Redefining Treatment Strategies in UC and CD
Peter D.R. Higgins, MD, PhD, MSc

8:40 AM
How to Assess and Treat Postoperative Crohn's Disease
Gary R. Lichtenstein, MD

9:00 AM
IBD Dilemmas Panel Discussion - Optimizing Treatment in Mild to Moderate IBD
Stephen B. Hanauer, MD

9:20 AM
Understanding Biological Therapies in IBD
Millie D. Long, MD, MPH

9:40 AM
Therapeutic Drug Monitoring to Optimize IBD Management
Stephen B. Hanauer, MD

10:00 AM
Posttest, Summary and Question and Answer

10:10 AM

10:25 AM
Novel Therapeutic Targets for IBD
Gary R. Lichtenstein, MD

10:50 AM
Approaches to Disease Monitoring and De-Escalation in IBD
Peter D.R. Higgins, MD, PhD, MSc

11:15 AM
Case Presentations: How Would You Treat?

11:45 AM
Improving the Patient Experience and Incorporating Patient Advocacy in IBD Care
Millie D. Long, MD, MPH

12:05 PM
Posttest, Summary and Question and Answer

12:15 PM

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review current guidelines on treat-to-target approaches in the management of IBD.

  • Assess and monitor disease severity in patients with IBD, using evidence-based modalities that improve the care of established and new patients.

  • Select treatment strategies in mild-to-moderate IBD that safely deliver the appropriate therapy and improve patient outcomes.

  • Incorporate the use of biologics, combination therapies, and emerging agents with novel mechanisms of action in patients with IBD refractory to current therapeutic options.

  • Incorporate the use of biomarkers and other therapeutic regimens that may improve patient outcomes and mucosal healing in IBD.

  • Apply therapeutic drug monitoring as needed to optimize the management of IBD.

  • Utilize guidelines-directed approaches for reducing the risk of disease recurrence after surgery for Crohn’s disease (CD).

  • Implement measures that improve patient communication, advocacy, and the use of shared decision-making to improve outcomes in IBD management.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with IBD.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by educational grants from AbbVie Inc. and Pfizer, Inc.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

Share with friends

Date and Time


Newport Beach Marriott Hotel and Spa

900 Newport Center Drive

Salon E&F, Lobby Level

Newport Beach, California 92660

View Map

Save This Event

Event Saved